Literature DB >> 24944553

Accuracy of prognostic and predictive markers in core needle breast biopsies compared with excisional specimens.

Mohammad Motamedolshariati1, Bahram Memar2, Mohsen Aliakbaian2, Mohammad T Shakeri3, Mohammad Samadi2, Ali Jangjoo2.   

Abstract

BACKGROUND: Core needle biopsy (CNB) is widely accepted for preoperative diagnosis of breast cancer and sometimes can be the only way of providing a suitable specimen for prognostic and predictive marker studies prior to neoadjuvant treatment. The purpose of this study was to evaluate the accuracy of CNB by comparing histological tumor type and grade as well as estrogen receptor (ER), progesterone receptor (PR), p53, and HER2/ neu status by immunohistochemistry in CNB and excisional surgical specimens. PATIENTS AND METHODS: During a 2.5-year study period, we identified 30 patients with breast cancer, who underwent CNB and definitive surgery. To evaluate the accuracy of CNB, tumor grade, ER, PR, HER2, and p53 status were immunohistochemically determined in both the CNB and the surgical specimens, and concordance of results between the 2 specimens was assessed.
RESULTS: The concordance rate was 100% for histological type, 66.6% for histological grade, and 96.7, 90, 76.7 and 93.3% for ER, PR, p53 and HER2/neu, respectively.
CONCLUSION: Our study showed that CNB has an excellent accuracy for tumor type, ER, and HER2/ neu; however, it should be used cautiously for tumor grade, PR, and p53 status. Thus, excisional biopsy is recommended for the determination of these factors.

Entities:  

Keywords:  Breast cancer; Core needle biopsy; Prognostic factors

Year:  2014        PMID: 24944553      PMCID: PMC4038314          DOI: 10.1159/000360787

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  17 in total

1.  Diagnostic accuracy of needle-localized open breast biopsy for impalpable breast disease.

Authors:  H M Verkooijen; P H Peeters; R M Pijnappel; V C Koot; M E Schipper; I H Borel Rinkes
Journal:  Br J Surg       Date:  2000-03       Impact factor: 6.939

Review 2.  An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens.

Authors:  E A Rakha; I O Ellis
Journal:  J Clin Pathol       Date:  2007-07-14       Impact factor: 3.411

3.  Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens?

Authors:  Chandra N Burge; Helena R Chang; Sophia K Apple
Journal:  Breast       Date:  2005-08-10       Impact factor: 4.380

4.  Impact of core-needle breast biopsy on the surgical management of mammographic abnormalities.

Authors:  R R White; T J Halperin; J A Olson ; M S Soo; R C Bentley; H F Seigler
Journal:  Ann Surg       Date:  2001-06       Impact factor: 12.969

5.  The accuracy of ultrasound, stereotactic, and clinical core biopsies in the diagnosis of breast cancer, with an analysis of false-negative cases.

Authors:  Mary F Dillon; Arnold D K Hill; Cecily M Quinn; Ann O'Doherty; Enda W McDermott; Niall O'Higgins
Journal:  Ann Surg       Date:  2005-11       Impact factor: 12.969

6.  Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer.

Authors:  G Bruce Mann; Vanessa D Fahey; Frank Feleppa; Malcolm R Buchanan
Journal:  J Clin Oncol       Date:  2005-08-01       Impact factor: 44.544

7.  A comparative analysis of core needle biopsy and final excision for breast cancer: histology and marker expression.

Authors:  Matthew Ough; Jose Velasco; Tina J Hieken
Journal:  Am J Surg       Date:  2010-09-18       Impact factor: 2.565

8.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.

Authors:  C W Elston; I O Ellis
Journal:  Histopathology       Date:  1991-11       Impact factor: 5.087

9.  Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma.

Authors:  Gavin C Harris; Helen E Denley; Sarah E Pinder; Andrew H S Lee; Ian O Ellis; Christopher W Elston; Andrew Evans
Journal:  Am J Surg Pathol       Date:  2003-01       Impact factor: 6.394

10.  Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC).

Authors:  M Arnedos; A Nerurkar; P Osin; R A'Hern; I E Smith; M Dowsett
Journal:  Ann Oncol       Date:  2009-07-01       Impact factor: 32.976

View more
  5 in total

1.  Aberrant miR-215 expression is associated with clinical outcome in breast cancer patients.

Authors:  Shu-wei Zhou; Bei-bei Su; Yong Zhou; Yue-qing Feng; Yu Guo; Yun-xiang Wang; Pan Qi; Sheng Xu
Journal:  Med Oncol       Date:  2014-10-01       Impact factor: 3.064

2.  Long Non-Coding RNA H19 Promotes Proliferation, Migration and Invasion and Inhibits Apoptosis of Breast Cancer Cells by Targeting miR-491-5p/ZNF703 Axis.

Authors:  Yongkun Wang; Zhen Wu; Yingxue Li; Zheng Zheng; Jinqiang Yan; Shuyan Tian; Lin Han
Journal:  Cancer Manag Res       Date:  2020-09-28       Impact factor: 3.989

3.  Nondestructive, multiplex three-dimensional mapping of immune infiltrates in core needle biopsy.

Authors:  Steve Seung-Young Lee; Vytautas P Bindokas; Mark W Lingen; Stephen J Kron
Journal:  Lab Invest       Date:  2018-11-06       Impact factor: 5.662

4.  Bioinformatic Identification of miR-622 Key Target Genes and Experimental Validation of the miR-622-RNF8 Axis in Breast Cancer.

Authors:  Chuanyang Liu; Lu Min; Jingyu Kuang; Chushu Zhu; Xin-Yuan Qiu; Lingyun Zhu
Journal:  Front Oncol       Date:  2019-10-23       Impact factor: 6.244

5.  A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer.

Authors:  Sirwan M Hadad; Lee B Jordan; Pankaj G Roy; Colin A Purdie; Takayuki Iwamoto; Lajos Pusztai; Stacy L Moulder-Thompson; Alastair M Thompson
Journal:  BMC Cancer       Date:  2016-09-22       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.